Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses

28 Jun 2024

Abstract excerpt

ABSTRACT: T-prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm associated with marked chemotherapy resistance and continued poor clinical outcomes. Current treatments, that is, the CD52-antibody alemtuzumab, offer transient responses, with relapses being almost inevitable without consolidating allogeneic transplantation. Recent more detailed concepts of T-PLL's pathobiology fostered the identification of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38941598
DOI: 10.1182/blood.2023022884

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responsesPMID 38941598Read ↗

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Semantic proximity Read ↗

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaSemantic proximity Read ↗

Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.Semantic proximity Read ↗

Discovery of molecularly-informed therapeutic strategies for mature T-cell neoplasmsSemantic proximity Read ↗

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read ↗

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read ↗

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)Semantic proximity Read ↗

BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulatorsSemantic proximity Read ↗

Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical StudiesSemantic proximity Read ↗

Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.